Eculizumab as a promising treatment in thymoma-associated myasthenia gravis

Myasthenia gravis is a chronic autoimmune disorder caused by antibodies directed against the neuromuscular junction. Some patients may have an associated thymoma, which confers a worse prognosis. Eculizumab, a monoclonal antibody that inhibits the activation of terminal complement, has recently been...

Descripción completa

Detalles Bibliográficos
Autores principales: Vélez-Santamaría, Valentina, Nedkova, Velina, Díez, Laura, Homedes, Christian, Alberti, M. Antonia, Casasnovas, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331764/
https://www.ncbi.nlm.nih.gov/pubmed/32655688
http://dx.doi.org/10.1177/1756286420932035
_version_ 1783553398655680512
author Vélez-Santamaría, Valentina
Nedkova, Velina
Díez, Laura
Homedes, Christian
Alberti, M. Antonia
Casasnovas, Carlos
author_facet Vélez-Santamaría, Valentina
Nedkova, Velina
Díez, Laura
Homedes, Christian
Alberti, M. Antonia
Casasnovas, Carlos
author_sort Vélez-Santamaría, Valentina
collection PubMed
description Myasthenia gravis is a chronic autoimmune disorder caused by antibodies directed against the neuromuscular junction. Some patients may have an associated thymoma, which confers a worse prognosis. Eculizumab, a monoclonal antibody that inhibits the activation of terminal complement, has recently been approved for the treatment of refractory generalized myasthenia gravis. This is an early case report of thymoma-associated refractory myasthenia gravis successfully treated with eculizumab in a real-world setting.
format Online
Article
Text
id pubmed-7331764
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-73317642020-07-10 Eculizumab as a promising treatment in thymoma-associated myasthenia gravis Vélez-Santamaría, Valentina Nedkova, Velina Díez, Laura Homedes, Christian Alberti, M. Antonia Casasnovas, Carlos Ther Adv Neurol Disord Case Report Myasthenia gravis is a chronic autoimmune disorder caused by antibodies directed against the neuromuscular junction. Some patients may have an associated thymoma, which confers a worse prognosis. Eculizumab, a monoclonal antibody that inhibits the activation of terminal complement, has recently been approved for the treatment of refractory generalized myasthenia gravis. This is an early case report of thymoma-associated refractory myasthenia gravis successfully treated with eculizumab in a real-world setting. SAGE Publications 2020-07-01 /pmc/articles/PMC7331764/ /pubmed/32655688 http://dx.doi.org/10.1177/1756286420932035 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Vélez-Santamaría, Valentina
Nedkova, Velina
Díez, Laura
Homedes, Christian
Alberti, M. Antonia
Casasnovas, Carlos
Eculizumab as a promising treatment in thymoma-associated myasthenia gravis
title Eculizumab as a promising treatment in thymoma-associated myasthenia gravis
title_full Eculizumab as a promising treatment in thymoma-associated myasthenia gravis
title_fullStr Eculizumab as a promising treatment in thymoma-associated myasthenia gravis
title_full_unstemmed Eculizumab as a promising treatment in thymoma-associated myasthenia gravis
title_short Eculizumab as a promising treatment in thymoma-associated myasthenia gravis
title_sort eculizumab as a promising treatment in thymoma-associated myasthenia gravis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331764/
https://www.ncbi.nlm.nih.gov/pubmed/32655688
http://dx.doi.org/10.1177/1756286420932035
work_keys_str_mv AT velezsantamariavalentina eculizumabasapromisingtreatmentinthymomaassociatedmyastheniagravis
AT nedkovavelina eculizumabasapromisingtreatmentinthymomaassociatedmyastheniagravis
AT diezlaura eculizumabasapromisingtreatmentinthymomaassociatedmyastheniagravis
AT homedeschristian eculizumabasapromisingtreatmentinthymomaassociatedmyastheniagravis
AT albertimantonia eculizumabasapromisingtreatmentinthymomaassociatedmyastheniagravis
AT casasnovascarlos eculizumabasapromisingtreatmentinthymomaassociatedmyastheniagravis

Ejemplares similares